ClinicalTrials.gov 临床试验·· 21 天前精选AI 评分48
cemiplimab辅助治疗术后非小细胞肺癌III期试验ARCH启动
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
AI 导读
ClinicalTrials.gov登记了一项名为ARCH的随机、分层、多中心III期试验,评估cemiplimab用于已手术切除、未接受过辅助含铂化疗的非小细胞肺癌患者的辅助免疫治疗。方案为cemiplimab 350 mg静脉给药每3周4个周期,随后700 mg每6周6个周期,直至复发或不可接受毒性。主要终点为无病生存期,与单纯观察对照,在中心确认PD-L1表达≥1%的患者中评估。
推荐理由
该试验在未接受过辅助化疗的术后NSCLC人群中对比cemiplimab与观察,可了解PD-L1≥1%人群的辅助免疫治疗设计。
来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov